Recently, Brastianos et al. completed the first non-randomized clinical trial studying safety and efficacy of combined BRAF and MEK inhibition in histopathological and genome sequencing proven V600E mutated papillary craniopharyngioma. This evidence concerns the gene BRAF and Papillary Craniopharyngioma.